Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462851 · ClinicalTrials.gov registry record · Phase 1
A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01462851 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 51 participants.
The verdict
NCT01462851, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is designed to observe the safety and concentrations of PF-05297909 and proteins in both blood and cerebrospinal fluid after a single dose of PF-05297909 in healthy adults.
Interventions
- DRUG PF-05297909 25 mg
- DRUG PF-05297909 100 mg
- DRUG PF-05297909 250 mg
- DRUG PF-05297909 525 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462851
The ClinicalTrials.gov registry entry for NCT01462851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-05297909 25 mg is the first listed.
NCT01462851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462851 about?
NCT01462851 is a clinical study titled "A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults". This study is designed to observe the safety and concentrations of PF-05297909 and proteins in both blood and cerebrospinal fluid after a single dose of PF-05297909 in healthy adults.
What is the current status of trial NCT01462851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2011-09. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01462851?
The interventions under investigation include: PF-05297909 25 mg (DRUG), PF-05297909 100 mg (DRUG), PF-05297909 250 mg (DRUG), PF-05297909 525 mg (DRUG).
Who is sponsoring clinical trial NCT01462851?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.